SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows

KIMS Hospitals launches Institute of Advanced Neurosciences in Bengaluru

New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery

India unveils first-ever national framework to tackle childhood diabetes

New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system

Fertin Pharma appoints Aditya Sharma as Managing Director for India operations

Healthcare and consumer wellness leader brings extensive experience in business transformation, commercial strategy and growth leadership to Fertin India

Karunanithi Ponnusamy elevated to President – Animal Health Business at Alembic Pharma

With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives

Health ministry releases new healthcare safety guidelines

Week-long Fire Safety Week 2026 campaign focuses on strengthening fire prevention, preparedness, audits, and emergency response across hospitals and healthcare facilities

HealthFab raises Rs 20 crore in Series A funding from Atomic Capital

Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions

Sankara Eye Hospital hosts ‘CSSD 360’ workshop on sterilisation and patient safety

Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings

FDA advisory panel backs AstraZeneca prostate cancer combo in decisive vote

The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer